Table 4

Comparison of patients treated with and without corticosteroids

No corticosteroids

(n = 103)

Corticosteroids

(n = 52)

Univariate analysis

OR (95%CI)

Multivariate analysis

OR (95%CI)


Comorbidity

Cardiovascular diseases

35

10

0.463 (0.208 - 1.031)

Chronic lung diseases

20

2

0.116 (0.037 - 0.740)

Symptoms at disease onset

Dyspnea

40

33

2.736 (1.373 - 5.452)

Hemoptysis

9

10

2.487 (0.942 - 6.568)

On hospital admission

Dyspnea

42

40

4.841 (2.275 - 10.304)

Pneumonia on CXR

81

48

3.259 (1.060 - 10.025)

Laboratory tests on admission

CPK

260 ± 447

577 ± 795

1.001 (1.000 - 1.002)

CK-MB

20 ± 30

32 ± 33

1.014 (0.997 - 1.032)

LDH, per 100 U/L increase

305 ± 229

658 ± 572

1.508 (1.219 - 1.866)

1.401 (1.107 - 1.773)

Complications

Acute respiratory failure

24 (23.3%)

38 (73.1%)

8.935 (4.160 - 19.187)

8.738 (2.504 - 30.489)

Septic shock

5 (4.9%)

13 (25.0%)

6.533 (2.183 - 19.551)

Acute renal failure

5 (4.9%)

10 (19.2%)

4.667 (1.503 - 14.486)

Altered mental status

9 (8.7%)

11 (21.2%)

2.842 (1.093 - 7.390)

Bloodstream infection

0

3

1.061 (0.992 - 1.135)

Other infections

1

4

8.500 (0.925 - 78.106)

Supportive treatment

Vasopresssors

9

19

6.013 (2.478 - 14.596)

Neuromuscular blockade

1

7

15.867 (1.896 - 132.776)

Noninvasive ventilation

11

21

5.666 (2.467 - 13.063)

Invasive ventilation

16

27

5.873 (2.742 - 12.578)


CK-MB, creatine kinase-MB; CPK, creatine phosphokinase; CXR, chest-X ray; LDH, lactate dehydrogenase

Xi et al. BMC Infectious Diseases 2010 10:256   doi:10.1186/1471-2334-10-256

Open Data